Introduction: The role of conformal radiotherapy (cRT) in thoracic esophageal squamous cell carcinoma (TESCC) has not been addressed in adjuvant settings. The aim of this study was to investigate whether postoperative radiotherapy using cRT after an R0 resection improves outcomes in pT3N0M0 TESCC compared with resection alone.
Introduction
Esophageal cancer is associated with a poor prognosis and substantial mortality rate. In China, esophageal cancer is the third most common cancer and the fourth leading cause of cancer death.
1 pT3N0M0 thoracic esophageal squamous cell carcinoma (TESCC) is locally advanced, but there are no regional lymph node or distant metastases. pT3 accounts for 51% and pN0 accounts for 56% of patients with resected TESCC. 2 Although surgical resection is the predominant treatment for M0 TESCC, the 5-year overall survival (OS) of pT2-3N0M0 TESCC after radical resection plus lymphadenectomy is only 28.5% to 57.0%, [2] [3] [4] [5] [6] [7] [8] [9] with an overall recurrence rate of 41.6% to 51.8% and a locoregional recurrence (LRR) rate of 33.3%. 4, 10 Although postoperative radiotherapy (PORT) after radical surgery has been reported to be beneficial for stage III or node-positive esophageal carcinoma, 5, 7, [11] [12] [13] [14] [15] [16] neither postoperative chemotherapy 17, 18 nor PORT 5, [19] [20] [21] [22] has provided a statistically significant survival benefit for pT3N0M0 TESCC in prospective studies. Xiao et al. 5 conducted a large phase III clinical trial of PORT in esophageal carcinoma and showed an improved 3-year OS in patients with pT2-3N0M0 TESCC who received PORT (64.0%) versus in those who received an operation alone (56.0%); however, the difference was not significant. Notably, all published prospective trials investigating PORT in TESCC were designed more than 20 years ago and used a conventional two-dimensional radiotherapy (2DRT) technique. More recently, conformal radiotherapy (cRT), including intensity-modulated radiotherapy (IMRT) and three-dimensional cRT (3D-cRT), have shown improved outcomes and decreased toxicities in a variety of cancers. [23] [24] [25] To date, the role of cRT has not been addressed in the adjuvant setting in TESCC. The purpose of this study was to investigate whether PORT using cRT after an R0 resection improves outcomes in pT3N0M0 TESCC compared with resection alone.
Methods

Eligibility
The medical records of patients with pT3N0M0 TESCC who were treated at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2004 to December 2011 were retrospectively reviewed. The inclusion criteria were (1) pT3N0M0 TESCC confirmed according to Union for International Cancer Control 2009 staging and (2) initial transthoracic subtotal esophagectomy plus lymphadenectomy. The exclusion criteria were (1) R1 or R2 surgery, (2) postoperative chemotherapy, (3) postoperative radiotherapy in another hospital, (4) loss to follow-up within 3 months of surgery, or (5) death within 3 months of surgery. The included patients were divided into two groups: a surgery plus cRT group (SþcRT group) comprising patients who underwent cRT after an R0 resection and a surgery group (S group) comprising a control group of patients who received an R0 resection alone (Fig. 1) . This study was approved by the ethics committee of our institution. Written informed consent was obtained from all patients.
Surgery
The surgical approach and procedure were determined by the tumor's location and the surgeon's preference. Right thoracotomy was the most common surgical approach for upper thoracic esophageal carcinoma. Left thoracotomy was the most common surgical approach for middle and lower thoracic esophageal carcinoma. Radical surgical resection consisted of a transthoracic subtotal esophagectomy, including abdominal and mediastinal lymphadenectomy. Then, a gastric tube through the posterior mediastinal route was used as a substitute for the resected esophagus to restore the continuity of the alimentary tract. The anastomotic site was dependent on tumor location. Generally, cervical anastomosis was performed in patients with upper thoracic esophageal lesions. Intrathoracic anastomosis at the level of the supraaortic arch was performed in patients with middle or lower thoracic esophageal lesions.
Postoperative Radiotherapy
Radiotherapy was initiated 4 to 10 weeks after surgery. Computed tomography (CT)-based definitions of anatomical landmarks were used to delineate mediastinal lymph node stations. 26 The primary site was defined according to Union for International Cancer Control 2002 staging. The clinical target volume (CTV) was defined as both tumor bed and lymphatic drainage areas at high risk. For patients with a gastric tube located at the primary esophageal bed after surgery, PORT was avoided in view of tolerance of the stomach. Anastomosis was included in the CTV for patients with upper thoracic tumors and patients who had an insufficient proximal margin (<3 cm). For upper thoracic tumors, the CTV borders were defined superiorly as the cricothyroid membrane and inferiorly as 2 to 3 cm below the trachea carina, including the lower cervical and supraclavicular region and mediastinal stations 1R/L, 2R/L, 3p, 4R/L, and 7. For middle thoracic tumors, the CTV borders were defined superiorly as the upper margin of the first thoracic vertebral body and inferiorly as 2 to 3 cm below the lower border of the tumor bed, including the lower cervical and supraclavicular region and mediastinal stations 1R/L, 2R/L, 3p, 4R/L, 7, and part of 8. For lower thoracic tumors, the CTV borders were defined superiorly as the upper margin of the first thoracic vertebral body and inferiorly as the left gastric region (including the supraclavicular regions; mediastinal stations 1R/L, 2R/L, 3p, 4R/L, 7, and 8; and paracardial and left gastric regions). A 5-mm 3D expansion of the CTV was used to create the corresponding planning target volume (PTV). A total dose of 50 to 60 Gy was delivered to 95% of the PTV in 25 to 33 fractions (five fractions per week) over 5 to 6.5 weeks by using 6-MV photon beams from a linear accelerator (Fig. 2) . Organs at risk (OAR), including the bilateral lungs, spinal cord, gastric tube, and heart, were contoured. The dose to the OAR was constrained as follows: maximal dose to the spinal cord less than 45 Gy, the percentage of irradiated bilateral lung volume exceeding 20 Gy equal to or less than 28%, the percentage of irradiated bilateral lung volume exceeding 30 Gy equal to or less than 20%, the percentage of irradiated heart volume exceeding 40 Gy less than 30%, the percentage of irradiated stomach volume exceeding 40 Gy equal to or less than 40%, and no hotspot on gastric tube.
Follow-up
Acute and late toxicities were scored according to the Common Toxicity Criteria for Adverse Events, version 3.0. All patients were assessed weekly during treatment and were followed up every 3 to 6 months during the first 2 years after treatment, every 6 to 12 months in the next 3 years, and annually thereafter. Assessments included a CT scan with contrast of the neck, thorax, and upper abdomen; ultrasonography of the neck and upper abdomen; nuclear bone scanning; and conventional blood and biochemistry studies. Esophagogastroendoscopy, positron emission tomography-CT (PET-CT), and fine-needle aspiration cytology were performed if needed.
Recurrences were classified as LRRs or distant metastases. LRRs were defined as recurrences at the supraclavicular, mediastinal, left gastric, or celiac trunk regions. Distant metastases were defined as recurrences at other sites. All recurrences were confirmed by a CT or magnetic resonance imaging scan of the corresponding site or an endoscopy. If necessary, cytologic or histologic examination was performed. Multiple recurrences detected within 1 month were considered synchronous. Localization and date of identification of recurrences were recorded. Losing follow-up within 3 months after surgery (n=13) Figure 1 . CONSORT diagram of patient selection. TESCC, thoracic esophageal squamous cell carcinoma; cRT, conformal radiotherapy; S, surgery.
OS was measured as the interval between the date of surgery and the date of death from any cause, loss to follow-up, or last follow-up. Disease-free survival (DFS) was measured as the interval between the date of surgery and the date of first recurrence, death from any cause, loss to follow-up, or last follow-up.
Statistical Analyses
Statistical analyses were performed with SPSS 20.0 software (IBM Corp., Armonk, NY) and STATA SE 12.0 (Stata Corp LP, College Station, TX). A chi-square test was used to compare categorical data, with or without correction for continuity. The Kaplan-Meier method was adopted to calculate the survival rate, and the log-rank method was used to compare survival curves between groups. A Cox regression model with stepwise selection was used to perform multivariate analyses of the effect of covariates on OS and DFS. To further adjust unbalanced covariates, a propensity score matching method 27 was used to create two comparable groups of patients: the SþcRT group and the S group. The propensity score for each patient was estimated with a logit model that included the following variables: age, sex, weight loss before surgery, tumor location, pathologic grade, proximal margin length, number of nodes resected, and lymphovacular invasion. Then, the nearest neighbor matching within a prespecified caliper width without replacement was used as the matching algorithm to perform 1:1 matching of patients in the SþcRT group and S group alone. The significance level was set as p less than 0.05.
Results
Patient Characteristics
A total of 678 patients were involved in this study, including 95 patients in the SþcRT group and 583 patients in the S group (see Fig. 1 ). In the SþcRT group , 83 patients received IMRT and 12 patients received 3D-cRT. Clinicopathologic characteristics were not significantly different between the groups, except that there were significantly fewer patients older than 60 years age in the SþcRT group than in the S group (Table 1) . The propensity score-matched cohort included 83 patients in the SþcRT group and 83 patients in the S group. There was an expected balance of covariates in the two groups (see Table 1 ).
Survival
Median follow-up across the whole study population was 63 months (range 3-127 months). Median follow-up was 60 months (range 3-122 months) in the SþcRT group and 66 months (range 3-127 months) in the S group. In the overall study cohort, the 3-and 5-year OS rates in the SþcRT group were 80.7% (95% confidence interval [CI]: 72.7-88.7%) and 75.2% (95% CI: 66.2-84.2%), respectively, and significantly higher than the 3-and 5-year OS rates in the S group (3-year OS ¼ 69.6%, 95% CI: 65.9-73.3% and 5-year OS ¼ 58.5%, 95% CI: 54.2-62.8%) (log-rank c 2 ¼ 8.361, p ¼0.004 [Fig. 3A] ). In the SþcRT group, the 3-and 5-year DFS rates were 73.3% (95% CI: 64.3-82.3%) and 71.8% (95% CI: 62.6-81.0%), respectively, and significantly higher than the 3-and 5-year DFS rates in the S group (3-year DFS ¼ 58.2%, 95% CI: 54.1-62.3% and 5-year DFS ¼ 49.2%, 95% CI: 44.9-53.5%) (log-rank c 2 ¼11.470, p ¼0.001 [ Fig. 3B]) . These findings were confirmed in the matched samples. In the SþcRT group, the 3-and 5-year OS rates were 81.8% and 75.7%, respectively, and significantly higher than the 3-and 5-year OS rates in the S group (3-year OS ¼ 65.5% and 5-year OS ¼ 58.8%) (log-rank c 2 ¼ 5.676, p ¼0.017 [ Fig. 4A] ). In the SþcRT group, the 3-and 5-year DFS rates were 73.4% and 71.7%, respectively, and significantly higher than the 3-and 5-year DFS rates in the S group (3-year DFS ¼ 52.7% and 
Recurrence
The analyses of recurrence included 95 patients in the SþcRT group and 527 patients in the S group, as detailed information on recurrence for 56 patients was unavailable. The rates of overall recurrence and LRR in the SþcRT group were significantly lower than in the S group (overall recurrence: log-rank c 2 ¼ 10.740, Fig 5A] ; LRR: log-rank c 2 ¼ 8.613, p ¼ 0.004, [Fig. 5B]) . The rate of distant metastasis in the SþcRT group was lower than in the S group, but the difference was not significant (log-rank c 2 ¼ 3.387, p ¼ 0.068 [ Fig. 5C ]). Table 1 , which demonstrates delivery of radiotherapy). Of the 13 patients who did not complete treatment on account 
Delivery of Radiotherapy
Discussion
In the current study, with a median follow-up of 63 months, cRT after radical resection was found to be tolerable and associated with significantly improved 5-year OS and DFS rates in pT3N0M0 TESCC. The survival benefits from postoperative cRT were maintained in the propensity score-matched analysis. Postoperative cRT, age 60 years or less, and more than 16 removed lymph nodes were independently associated with longer OS. PORT was an independent prognostic factor for DFS.
To the authors' knowledge, the current study is the first to report a survival benefit from cRT in the PORT setting for pT3N0M0 TESCC. The benefit of PORT and multimodal treatment for TESCC remains controversial owing to a lack of conclusive evidence. [28] [29] [30] [31] Several retrospective studies have shown that PORT improves OS for stage III and node-positive TESCC, 7, [11] [12] [13] [14] [15] [16] which suggests the need to revaluate the role of PORT in esophageal carcinoma.
Previous studies reported overall recurrence and LRR rates after radical surgery for stage pT2-3N0M0 TESCC at 41.6% to 51.8% and 33.3%, 4,10 respectively, and no survival benefit for patients who received PORT. 5, 7, 11, 12, 14, 32 Two of these studies used 2DRT, 5, 11 and the radiation technique is unknown in the other four. 7, 12, 14, 32 In the modern era, 3D-cRT and IMRT techniques are widely used in clinical practice. Compared with 2DRT, 3D-cRT enables a vastly superior target volume delineation and radiation planning, resulting in the delivery of a high homogenous dose to the PTV and a lower dose to the OAR. Both randomized and nonrandomized studies show that cRT is associated with less radiation-related toxicity in a variety of tumors, 33, 34 and a survival benefit from cRT compared with 2DRT has been reported in nasopharyngeal cancer and NSCLC. 23, 24 In esophageal cancer, IMRT significantly reduces toxicities and non-cancer-related death compared with 3D-cRT, but whether IMRT is associated with a survival benefit is currently unclear. 35, 36 Previously, we reported an improvement in OS from IMRT after radical surgery for node-positive or stage III TESCC. 16 The results of the current study indicate that postoperative cRT may improve OS and DFS in patients with pT3N0M0 TESCC.
The target volume for PORT in esophageal cancer is extremely important but not well established. In clinical practice, optimization of PORT CTV is determined by the risk of recurrence. Lymph node recurrence rates (LNRRs) in the supraclavicular and upper mediastinal regions are 29.5% and 46.7%, respectively, which is much higher than in the lower mediastinal or upper abdominal region. 37, 38 LNRRs in the upper abdominal regions are 2.3% to 18.3%, with higher LNRRs in patients with lower thoracic esophageal cancers or positive lymph nodes. 3, 39, 40 Importantly, node-negative TESCC has a significantly lower LNRR than node-positive TESCC.
3,4,37,38 Accordingly, to reduce toxicity with an appropriate target volume, we recommend that the PORT CTV for node-negative TESCC differ from that for node-positive TESCC.
In 2004, we recommended PORT for pT3N0M0 TESCC on the basis of the following facts: (1) although prospective studies indicated that PORT did not improve survival, PORT consistently reduced LRR in nodenegative TESCC after radical surgery in both our trial 40 and a study in France 19 ; and (2) cRT may be associated with reduced toxicity compared with 2DRT in TESCC. In view of the rate of overall recurrence, 3, 4, 37, 38 especially upper abdominal recurrence, 40 of node-negative TESCC after radical surgery is significantly lower than that of node-positive disease, we modified the radiation target volume and proposed a stratified design for administration of PORT in TESCC, which is seen in this study for node-negative TESCC and in our previous report for node-positive or stage III TESCC. 16 Consequently, the current study demonstrates the safety and clinical feasibility of the modified radiation regimen. Additionally, the reduced recurrence and improved survival in the current study supports its efficacy. Even though a minority of patients in this study underwent PORT on account of the lack of evidence from randomized trials supporting PORT in pT3N0M0 TESCC, this is the first study with a large sample focusing on the role of postoperative cRT in this patient population.
The PORT radiation dose in TESCC is also controversial and not well established. Previous studies have used a total dose ranging from 45 Gy to 60 Gy at 1.8 to 2 Gy per fraction. 5, 19, 22, [41] [42] [43] In the current study, 50 to 60 Gy improved OS with tolerable toxicity, which suggests that 50 to 60 Gy is reasonable. This is confirmed by reports that recommend a dose of 50 Gy or more for postoperative chemoradiotherapy in TESCC. 42, 43 However, further studies are needed to determine the optimal PORT radiation dose in TESCC.
There were several limitations associated with this study. First, this is a retrospective analysis. However, we mimicked randomization through propensity score matching, which eliminated potential bias by creating two comparable groups. Second, this was a singleinstitution study. However, this guaranteed homogeneity of treatment, and the large sample size focused on a single TESCC stage enhanced the reliability of the results.
In conclusion, PORT using cRT per our modified radiation regimen is strongly associated with an improved OS and DFS in patients with pT3N0M0 TESCC. A multicenter, randomized phase III clinical trial is warranted to confirm our findings.
